News
THOR
--
0.00%
--
Monday Morning Market Highlights
GuruFocus.com · 06/08 18:11
Sanofi finalizes Synthorx buy
seekingalpha · 01/23 19:46
IBKC, THOR, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
GlobeNewswire · 01/09 18:15
WAAS, TIVO, THOR, and CRCM SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
GlobeNewswire · 01/07 05:00
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm
PR Newswire · 01/06 16:07
CBB, TGE, INST, and THOR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
GlobeNewswire · 01/02 20:00
THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
GlobeNewswire · 12/28/2019 19:00
Can Winnebago Replicate This Year's Stellar Show in 2020?
Zacks · 12/27/2019 13:47
The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 26.)
Benzinga · 12/27/2019 12:59
The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.)
Benzinga · 12/26/2019 12:55
Why A Bidding War For Synthorx Bodes Well For This Biotech Stock
Investor's Business Daily · 12/24/2019 18:09
Biotech Leading in Q4: Best ETFs & Stocks
Zacks · 12/24/2019 17:15
10 Biotech M&A Targets Under The Scanner For 2020
Biopharma M&A activity scaled record highs in 2019, with a few mega mergers announced involving names such as Bristol-Myers Squibb Co (NYSE: BMY), Roche Holdings AG Basel ADR (OTC: RHHBY) and AbbVie Inc
Benzinga · 12/24/2019 12:31
Pharma M&A Deals Likely To Be Smaller in 2020
GuruFocus.com · 12/23/2019 21:12
A Perspective On Biopharma's Record M&A Run In 2019
This year was a watershed one for biopharma M&A, with several multibillion-dollar deals announced thus far.
Benzinga · 12/23/2019 19:57
INST, THOR, AMTD, and AKS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
GlobeNewswire · 12/23/2019 14:00
Moving Average Crossover Alert: Synthorx
Zacks · 12/23/2019 13:34
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, INST, THOR
GlobeNewswire · 12/21/2019 16:44
Jefferies Downgrades Synthorx to Hold, Raises Price Target to $68
Jefferies analyst Biren Amin downgrades Synthorx (NASDAQ:THOR) from Buy to Hold and raises the price target from $23 to $68.
Benzinga · 12/19/2019 11:34
Hedge Funds Have Never Been More Bullish On Synthorx, Inc. (THOR)
Insider Monkey · 12/17/2019 21:39
Webull provides a variety of real-time THOR stock news. You can receive the latest news about Synthorx through multiple platforms. This information may help you make smarter investment decisions.
About THOR
Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
More